Roswell Park study: Targeting HSP60-ClpP axis may improve outcomes in prostate cancer

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

Avenda Health has announced study results showing that its cancer mapping tool, Unfold AI, predicts cancer spread more accurately than MRI.

May 02, 2025

Vol.51 No.17

Clinical Roundup

Cleveland Clinic Abu Dhabi performs first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer

Cleveland Clinic Abu Dhabi, in collaboration with experts from Cleveland Clinic in the U.S., performed the world’s first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer.

April 25, 2025

Vol.51 No.16

Obituary

Thomas B. Tomasi Jr., Roswell Park president and CEO from 1986 to 1996, dies at 97
An architect of today’s Roswell Park

Thomas B. Tomasi Jr., who led Roswell Park Comprehensive Cancer Center as president and CEO from 1986 to 1996, died March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers.

April 11, 2025

Vol.51 No.14

By Roswell Park Comprehensive Cancer Center

Clinical Roundup

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.

April 11, 2025

Vol.51 No.14

Drugs & Targets

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

Clinical Roundup

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.

March 21, 2025

Vol.51 No.11

Roswell Park study: Targeting HSP60-ClpP axis may improve outcomes in prostate cancer

YOU MAY BE INTERESTED IN

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

Cleveland Clinic Abu Dhabi performs first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer

Thomas B. Tomasi Jr., Roswell Park president and CEO from 1986 to 1996, dies at 97
An architect of today’s Roswell Park

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

FDA approves prostate cancer imaging agent Gozellix

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Renew today!

Subscriber content

Never miss an issue!

Login

Roswell Park study: Targeting HSP60-ClpP axis may improve outcomes in prostate cancer

YOU MAY BE INTERESTED IN

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

Cleveland Clinic Abu Dhabi performs first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer

Thomas B. Tomasi Jr., Roswell Park president and CEO from 1986 to 1996, dies at 97An architect of today’s Roswell Park

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

FDA approves prostate cancer imaging agent Gozellix

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Never miss an issue!

Login

Thomas B. Tomasi Jr., Roswell Park president and CEO from 1986 to 1996, dies at 97
An architect of today’s Roswell Park